Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise for Hard-to-Treat breast cancer

NCT ID NCT06686394

Recruiting now Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called patritumab deruxtecan in people with HER2-positive breast cancer that has spread or cannot be removed by surgery. The goal is to see if the drug can shrink tumors and how safe it is. About 81 adults will take part. This is not a cure, but aims to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER BREAST NEOPLASMS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Asan Medical Center ( Site 0031)

    RECRUITING

    Seoul, 05505, South Korea

    Contact Phone: •••-•••-••••

  • Centre Hospitalier de l'Université de Montréal ( Site 0004)

    RECRUITING

    Montreal, Quebec, H2X 3E4, Canada

    Contact Phone: •••-•••-••••

  • Dana-Farber Cancer Institute ( Site 0050)

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-••••

  • Inova Schar Cancer Institute ( Site 0051)

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact Phone: •••-•••-••••

  • Jewish General Hospital ( Site 0003)

    RECRUITING

    Montreal, Quebec, H3T 1E2, Canada

    Contact Phone: •••-•••-••••

  • Kingston General Hospital ( Site 0061)

    RECRUITING

    Kingston, Ontario, K7L 2V7, Canada

    Contact Phone: •••-•••-••••

  • Nagoya City University Hospital ( Site 0020)

    RECRUITING

    Nagoya, Aichi-ken, 467-8602, Japan

    Contact Phone: •••-•••-••••

  • Princess Margaret Cancer Centre ( Site 0001)

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

    Contact Phone: •••-•••-••••

  • Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053)

    RECRUITING

    Greenville, South Carolina, 29605, United States

    Contact Phone: •••-•••-••••

  • Rabin Medical Center ( Site 0012)

    RECRUITING

    Petah Tikva, 4941492, Israel

    Contact Phone: •••-•••-••••

  • Rambam Health Care Campus ( Site 0011)

    RECRUITING

    Haifa, 3109601, Israel

    Contact Phone: •••-•••-••••

  • Rutgers Cancer Institute of New Jersey ( Site 0052)

    RECRUITING

    New Brunswick, New Jersey, 08901, United States

    Contact Phone: •••-•••-••••

  • Seoul National University Hospital ( Site 0030)

    RECRUITING

    Seoul, 03080, South Korea

    Contact Phone: •••-•••-••••

  • Sheba Medical Center ( Site 0010)

    RECRUITING

    Ramat Gan, 5265601, Israel

    Contact Phone: •••-•••-••••

  • St Bartholomew s Hospital ( Site 0040)

    RECRUITING

    London, London, City of, EC1A 7BE, United Kingdom

    Contact Phone: •••-•••-••••

  • The Beatson West of Scotland Cancer Centre ( Site 0043)

    RECRUITING

    Glasgow, Glasgow City, G12 0YN, United Kingdom

    Contact Phone: •••-•••-••••

  • University College London Hospital ( Site 0041)

    RECRUITING

    London, Camden, NW1 2PG, United Kingdom

    Contact Phone: •••-•••-••••

  • University of Colorado Anschutz Medical Campus ( Site 0057)

    RECRUITING

    Aurora, Colorado, 80045, United States

    Contact Phone: •••-•••-••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.